The long term goals of our laboratory are to understand the cellular mechanisms that regulate endothelial dysfunction during inflammatory and neoplastic conditions with a hope to use this knowledge in designing novel therapeutic agents.  We are particularly interested in the role of intracellular oxidants as mediators of cytokine and growth factor signaling, endothelial-dependent regulation of tumor proliferation and angiogenesis in endocrine tumors, including thyroid cancer.  Understanding these mechanisms will facilitate the development of targeted therapy and reliable biomarkers for recurrent and metastatic thyroid cancer. 

Our strategies include the use of biochemical inhibitors, chemotherapeutic agents, siRNA, and mutated plasmids to interrogate known signaling pathways.  Other techniques include trans-monolayer electrical resistance, and genetic profiling.  We use an orthopic tumor model of thyroid cancer to evaluate tumor and host angiogenic activity.

We anticipate these these studies will provide important information which will be helpful for designing clinical studies for advanced thyroid cancer.  Our laboratory is also interested in developing novel models of drug delivery using nanotechnology.